138 related articles for article (PubMed ID: 30289818)
1. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
[TBL] [Abstract][Full Text] [Related]
2. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
3. Creation of a long-acting rilpivirine prodrug nanoformulation.
Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.
McMillan J; Szlachetka A; Slack L; Sillman B; Lamberty B; Morsey B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061742
[TBL] [Abstract][Full Text] [Related]
5. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
Andrews CD; Bernard LS; Poon AY; Mohri H; Gettie N; Spreen WR; Gettie A; Russell-Lodrigue K; Blanchard J; Hong Z; Ho DD; Markowitz M
AIDS; 2017 Feb; 31(4):461-467. PubMed ID: 27902508
[TBL] [Abstract][Full Text] [Related]
6. A year-long extended release nanoformulated cabotegravir prodrug.
Kulkarni TA; Bade AN; Sillman B; Shetty BLD; Wojtkiewicz MS; Gautam N; Hilaire JR; Sravanam S; Szlachetka A; Lamberty BG; Morsey BM; Fox HS; Alnouti Y; McMillan JM; Mosley RL; Meza J; Domanico PL; Yue TY; Moore G; Edagwa BJ; Gendelman HE
Nat Mater; 2020 Aug; 19(8):910-920. PubMed ID: 32341511
[TBL] [Abstract][Full Text] [Related]
7. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.
Gautam N; McMillan JM; Kumar D; Bade AN; Pan Q; Kulkarni TA; Li W; Sillman B; Smith NA; Shetty BLD; Szlachetka A; Edagwa BJ; Gendelman HE; Alnouti Y
Nat Commun; 2021 Jun; 12(1):3453. PubMed ID: 34103484
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a long-acting nanoformulated abacavir prodrug.
Singh D; McMillan J; Hilaire J; Gautam N; Palandri D; Alnouti Y; Gendelman HE; Edagwa B
Nanomedicine (Lond); 2016 Aug; 11(15):1913-27. PubMed ID: 27456759
[TBL] [Abstract][Full Text] [Related]
9. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
Pons-Faudoa FP; Sizovs A; Di Trani N; Paez-Mayorga J; Bruno G; Rhudy J; Manohar M; Gwenden K; Martini C; Chua CYX; Varchi G; Marzinke MA; Grattoni A
J Control Release; 2019 Jul; 306():89-96. PubMed ID: 31136811
[TBL] [Abstract][Full Text] [Related]
10. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat.
Jucker BM; Alsaid H; Rambo M; Lenhard SC; Hoang B; Xie F; Groseclose MR; Castellino S; Damian V; Bowers G; Gupta M
J Control Release; 2017 Dec; 268():102-112. PubMed ID: 29042321
[TBL] [Abstract][Full Text] [Related]
11. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
Reese MJ; Bowers GD; Humphreys JE; Gould EP; Ford SL; Webster LO; Polli JW
Xenobiotica; 2016; 46(5):445-56. PubMed ID: 26340566
[TBL] [Abstract][Full Text] [Related]
12. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
Ford SL; Lou Y; Lewis N; Kostapanos M; D'Amico R; Spreen W; Patel P
Antivir Ther; 2019; 24(4):301-308. PubMed ID: 30896438
[TBL] [Abstract][Full Text] [Related]
13. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects.
Spreen W; Ford SL; Chen S; Wilfret D; Margolis D; Gould E; Piscitelli S
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):481-6. PubMed ID: 25140909
[TBL] [Abstract][Full Text] [Related]
14. Cabotegravir and rilpivirine for the treatment of HIV.
Rial-Crestelo D; Pinto-Martínez A; Pulido F
Expert Rev Anti Infect Ther; 2020 May; 18(5):393-404. PubMed ID: 32164474
[No Abstract] [Full Text] [Related]
15. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
Rajoli RKR; Back DJ; Rannard S; Meyers CF; Flexner C; Owen A; Siccardi M
Clin Pharmacokinet; 2018 Feb; 57(2):255-266. PubMed ID: 28540638
[TBL] [Abstract][Full Text] [Related]
16. Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine.
Guo D; Zhou T; Araínga M; Palandri D; Gautam N; Bronich T; Alnouti Y; McMillan J; Edagwa B; Gendelman HE
J Acquir Immune Defic Syndr; 2017 Mar; 74(3):e75-e83. PubMed ID: 27559685
[TBL] [Abstract][Full Text] [Related]
17. Cabotegravir long-acting for HIV-1 prevention.
Andrews CD; Heneine W
Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
[TBL] [Abstract][Full Text] [Related]
19. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.
Kraft JC; McConnachie LA; Koehn J; Kinman L; Collins C; Shen DD; Collier AC; Ho RJ
AIDS; 2017 Mar; 31(6):765-770. PubMed ID: 28099191
[TBL] [Abstract][Full Text] [Related]
20. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
Ford SL; Sutton K; Lou Y; Zhang Z; Tenorio A; Trezza C; Patel P; Spreen W
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
